Pityriasis rosea following CoronaVac COVID‐19 vaccination: a case report

Akdaş, Elçin; İlter, Nilsel; Öğüt, Betül; Erdem, Özlem

doi:10.1111/jdv.17316

Cited by 29 publications

(36 citation statements)

References 6 publications

(13 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The patient developed papulovesicular lesions in the crease lines of the trunk and extremities, four days after inoculation with a recombinant coronavirus vaccine (Covishield™, India). Among patients who received inactivated vaccines, another case of PR-like eruption was reported four days after the first dose of CoronaVac® (SinoVac) ( 1 ). Here, we report the first case of PR-like eruption following ChAdOx1 nCoV-19 (Oxford/AstraZeneca) vaccination.…”

Section: Discussionmentioning

confidence: 99%

Case Report: Pityriasis Rosea-Like Eruption Following COVID-19 Vaccination

2021

View full text Add to dashboard Cite

Vaccination is one of the cornerstones in the efforts towards ending the coronavirus disease 2019 (COVID-19) pandemic. However, several adverse effects of COVID-19 vaccination have been identified. Pityriasis rosea (PR)-like eruption is a rare cutaneous complication of immunization. To the best of our knowledge, there have been no reports of PR-like eruptions following inoculation with Oxford/AstraZeneca ChAdOx1 nCoV-19 (AZD1222) vaccine. Here, we described a case of PR-like eruption that developed 14 days after Oxford/AstraZeneca vaccination in a 52-year-old Thai woman with glioblastoma. Treatment with topical 0.1% triamcinolone acetonide twice per day showed partial response after seven days. Despite this rare complication, our report highlights that the presence of PR-like eruption is not a contraindication for subsequent vaccinations.

show abstract

Section: Discussionmentioning

confidence: 99%

Case Report: Pityriasis Rosea-Like Eruption Following COVID-19 Vaccination

2021

View full text Add to dashboard Cite

show abstract

“…Akdas et al. 16 described a case report of pityriasis rosea (PR) in a 45‐year‐old woman with no history of allergies. PR was developed 4 days after receiving the first dose.…”

Section: Leading Covid‐19 Vaccine Candidatesmentioning

confidence: 99%

“…Rare adverse events have also been described following the immunisation with CoronaVac, AZD1222, Ad26.COV2.S, BNT162b2 and mRNA‐1273. 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 However, causal links between Covid‐19 vaccines and rare adverse events have not been established.…”

Section: Introductionmentioning

confidence: 99%

Covid‐19 vaccines and variants of concern: A review

Hassine

2021

Reviews in Medical Virology

275

178

View full text Add to dashboard Cite

Since the outbreak of coronavirus disease 2019 (Covid‐19) in December 2019, caused by the severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), the number of confirmed infections has risen to more than 242 million worldwide, with nearly 5 million deaths. Currently, nine Covid‐19 vaccine candidates based on the original Wuhan‐Hu‐1 strain are at the forefront of vaccine research. All nine had an efficacy over 50% against symptomatic Covid‐19 disease: NVX‐CoV2373 (∼96%), BNT162b2 (∼95%), mRNA‐1273 (∼94%), Sputnik V (∼92%), AZD1222 (∼81%), BBIBP‐CorV (∼79%), Covaxin (∼78%), Ad26.CoV.S (∼66%) and CoronaVac (∼51%). However, vaccine efficacy (VE) can be jeopardised by the rapid emergence and spread of SARS‐CoV‐2 variants of concern (VOCs) that could escape from neutralising antibodies and/or cell‐mediated immunity. Rare adverse events have also been reported soon after administration of viral vector and mRNA vaccines. Although many Covid‐19 vaccines have been developed, additional effective vaccines are still needed to meet the global demand. Promising Covid‐19 vaccines such as WIBP‐CorV, AD5‐nCOV, ZyCoV‐D, CVnCoV, EpiVacCorona and ZF2001 have advanced to clinical studies. This review describes the most relevant mutations in the SARS‐CoV‐2 spike protein, discusses VE against VOCs, presents rare adverse events after Covid‐19 vaccination and introduces some promising Covid‐19 vaccine candidates.

show abstract

“…A case report stated the development of SDRIFE like eruptions and itchy rashes 4 days after CoronaVac in an 87-year-old patient, though the specific allergen could not be identified yet [ 215 ]. In a 45-year-old female healthcare worker of Turkey, pityriasis rosea (skin rashes, herald patch, multiple plaques in chest region), generally caused by the herpes virus and rarely caused after vaccination developed 4 days after both the first and the second dose of CoronaVac which cured within few weeks on treatment [ 216 ]. Though when compared to life threats skin eruptions are somewhat acceptable, close monitoring may be recommended as the mechanism behind the development of this side effect is not clear yet.…”

Section: Vaccines Approved For Public Usementioning

confidence: 99%

Counting on COVID-19 Vaccine: Insights into the Current Strategies, Progress and Future Challenges

et al. 2021

View full text Add to dashboard Cite

The emergence of a novel coronavirus viz., severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in late 2019 and its subsequent substantial spread produced the coronavirus disease 2019 (COVID-19) pandemic worldwide. Given its unprecedented infectivity and pathogenicity, the COVID-19 pandemic had a devastating impact on human health, and its clinical management has been a great challenge, which has led to the development and speedy trials of several vaccine candidates against SARS-CoV-2 at an exceptional pace. As a result, several COVID-19 vaccines were made commercially available in the first half of 2021. Although several COVID-19 vaccines showed promising results, crucial insights into their epidemiology, protective mechanisms, and the propensities of reinfection are not largely reviewed. In the present report, we provided insights into the prospects of vaccination against COVID-19 and assessed diverse vaccination strategies including DNA, mRNA, protein subunits, vector-based, live attenuated, and inactivated whole/viral particle-based vaccines. Next, we reviewed major aspects of various available vaccines approved by the World Health Organization and by the local administrations to use against COVID-19. Moreover, we comprehensively assessed the success of these approved vaccines and also their untoward effects, including the possibility of reinfection. We also provided an update on the vaccines that are under development and could be promising candidates in the future. Conclusively, we provided insights into the COVID-19 vaccine epidemiology, their potency, and propensity for SARS-CoV-2 reinfection, while a careful review of their current status, strategies, success, and future challenges was also presented.

show abstract

Pityriasis rosea following CoronaVac COVID‐19 vaccination: a case report

Cited by 29 publications

References 6 publications

Case Report: Pityriasis Rosea-Like Eruption Following COVID-19 Vaccination

Case Report: Pityriasis Rosea-Like Eruption Following COVID-19 Vaccination

Covid‐19 vaccines and variants of concern: A review

Counting on COVID-19 Vaccine: Insights into the Current Strategies, Progress and Future Challenges

Contact Info

Product

Resources

About